Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivoKoji Tsumagari(Tulane University), Emad Kandil(Tulane University)Endocrine Related CancerDecember 22, 201710.1530/erc-17-0182Cited by 28SaveCiteExport RISWatch citationsRelated PapersAssociation of allelic loss at 8p22 with poor prognosis among breast cancer cases treated with high-dose adjuvant chemotherapy|Cancer Letters|2002|64New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking|Cells|2021|19